糖尿病：2型糖尿病中二甲双胍的附加治疗——利格列汀还是格列美脲？ - Suppr

Suppr

超能文献

Diabetes: Add-on to metformin in T2DM--linagliptin or glimepiride?

作者信息

Christensen Mikkel, Knop Filip K

出版信息

Nat Rev Endocrinol. 2012 Oct;8(10):576-8. doi: 10.1038/nrendo.2012.163. Epub 2012 Aug 28.

DOI:10.1038/nrendo.2012.163

PMID:22926098

Abstract

摘要

相似文献

Diabetes: Add-on to metformin in T2DM--linagliptin or glimepiride?糖尿病：2型糖尿病中二甲双胍的附加治疗——利格列汀还是格列美脲？

Nat Rev Endocrinol. 2012 Oct;8(10):576-8. doi: 10.1038/nrendo.2012.163. Epub 2012 Aug 28.

Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.利那格列汀单药治疗二甲双胍不适用的2型糖尿病患者：一项为期18周的随机、双盲、安慰剂对照III期试验及为期34周的活性药物对照延长期试验

Diabetes Obes Metab. 2012 Dec;14(12):1145-54. doi: 10.1111/dom.12011. Epub 2012 Oct 1.

2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial.二甲双胍控制不佳的 2 型糖尿病患者中利拉利汀与格列美脲的 2 年疗效和安全性比较：一项随机、双盲、非劣效性试验。

Lancet. 2012 Aug 4;380(9840):475-83. doi: 10.1016/S0140-6736(12)60691-6. Epub 2012 Jun 28.

Gliptin versus a sulphonylurea as add-on to metformin.与磺脲类药物相比，格列汀作为二甲双胍的附加治疗药物

Lancet. 2012 Aug 4;380(9840):450-2. doi: 10.1016/S0140-6736(12)60859-9. Epub 2012 Jun 28.

Efficacy and safety of linagliptin in subjects with type 2 diabetes mellitus and poor glycemic control: pooled analysis of data from three placebo-controlled phase III trials.在血糖控制不佳的 2 型糖尿病患者中，利拉利汀的疗效和安全性：来自三项安慰剂对照 III 期临床试验数据的汇总分析。

J Diabetes Complications. 2013 May-Jun;27(3):274-9. doi: 10.1016/j.jdiacomp.2012.11.008. Epub 2013 Feb 9.

DPP-4 inhibition and neuroprotection: do mechanisms matter?二肽基肽酶-4抑制与神经保护：作用机制重要吗？

Diabetes. 2013 Apr;62(4):1029-31. doi: 10.2337/db12-1794.

Effect of linagliptin compared with glimepiride on postprandial glucose metabolism, islet cell function and vascular function parameters in patients with type 2 diabetes mellitus receiving ongoing metformin treatment.与格列美脲相比，利格列汀对正在接受二甲双胍治疗的2型糖尿病患者餐后葡萄糖代谢、胰岛细胞功能和血管功能参数的影响。

Diabetes Metab Res Rev. 2014 Oct;30(7):582-9. doi: 10.1002/dmrr.2525.

A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes.一项随机、活性药物与安慰剂对照的三阶段交叉试验，旨在研究二肽基肽酶-4抑制剂利格列汀对2型糖尿病患者大血管和微血管内皮功能的短期影响。

Cardiovasc Diabetol. 2017 Jan 21;16(1):13. doi: 10.1186/s12933-016-0493-3.

Linagliptin: a review of its use in the management of type 2 diabetes mellitus.利拉鲁肽：在 2 型糖尿病管理中的应用评价。

Drugs. 2012 Sep 10;72(13):1793-824. doi: 10.2165/11209570-000000000-00000.

Frailty and diabetes.

Lancet. 2013 Oct 26;382(9902):1386-7. doi: 10.1016/S0140-6736(13)61676-1. Epub 2013 Aug 13.

本文引用的文献

Lancet. 2012 Aug 4;380(9840):475-83. doi: 10.1016/S0140-6736(12)60691-6. Epub 2012 Jun 28.

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).2型糖尿病高血糖管理：以患者为中心的方法。美国糖尿病协会（ADA）和欧洲糖尿病研究协会（EASD）的立场声明。

Diabetologia. 2012 Jun;55(6):1577-96. doi: 10.1007/s00125-012-2534-0. Epub 2012 Apr 20.

Differential effects of sulfonylurea derivatives on vascular ATP-sensitive potassium channels.磺酰脲类衍生物对血管三磷酸腺苷敏感性钾通道的影响差异。

Eur J Pharmacol. 2012 Apr 15;681(1-3):75-9. doi: 10.1016/j.ejphar.2012.02.006. Epub 2012 Feb 17.

The effect of glucagon-like peptide 1 on cardiovascular risk.胰高血糖素样肽 1 对心血管风险的影响。

Nat Rev Cardiol. 2012 Jan 31;9(4):209-22. doi: 10.1038/nrcardio.2011.211.

The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study.2 型糖尿病患者症状性、严重低血糖与死亡的相关性：ACCORD 研究的回顾性流行病学分析。

BMJ. 2010 Jan 8;340:b4909. doi: 10.1136/bmj.b4909.

Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes.维格列汀可增强2型糖尿病患者胰岛对高血糖和低血糖的反应性。

J Clin Endocrinol Metab. 2009 Apr;94(4):1236-43. doi: 10.1210/jc.2008-2152. Epub 2009 Jan 27.

Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration.1型和2型糖尿病患者低血糖风险：治疗方式及其疗程的影响

Diabetologia. 2007 Jun;50(6):1140-7. doi: 10.1007/s00125-007-0599-y. Epub 2007 Apr 6.

Sulfonylurea induced beta-cell apoptosis in cultured human islets.磺脲类药物诱导培养的人胰岛β细胞凋亡。

J Clin Endocrinol Metab. 2005 Jan;90(1):501-6. doi: 10.1210/jc.2004-0699. Epub 2004 Oct 13.

Oral glibenclamide suppresses glucagon secretion during insulin-induced hypoglycemia in patients with type 2 diabetes.

J Clin Endocrinol Metab. 1999 Sep;84(9):3140-5. doi: 10.1210/jcem.84.9.6002.

U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group.英国前瞻性糖尿病研究16。2型糖尿病6年治疗概述：一种进行性疾病。英国前瞻性糖尿病研究小组。

Diabetes. 1995 Nov;44(11):1249-58.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验